In line with the partnership with Janssen Pharmaceutica NV, Mundipharma now exclusively distributes and markets these treatments across 18 countries in the European Economic Area (EEA) and Switzerland.
The post Mundipharma launches Invokana and Vokanamet in Norway for treatment of type 2 diabetes appeared first on Pharmaceutical Business review.